To our Valued Clients and Business Partners, VGXI’s top priority is to continue delivering the highest quality DNA products and services while ensuring the security and safety of our team. VGXI is actively monitoring the evolving situation and will continue to provide updates as new information becomes available. Manufacturing activities have been… Read More »
VGXI opened the doors of its new headquarters and manufacturing facility on 09Apr22 to provide friends and employee families a first look inside and outside the new site! As production is nearing completion, the event was an opportunity for employees and their families to tour the production suites, labs, and office spaces… Read More »
Texas-based CDMO VGXI, Inc. is excited to announce that its partner, The Institute for Molecular Medicine, has recently been awarded a $12 million NIA grant to support clinical testing of a novel DNA vaccine manufactured by VGXI for the prevention of Alzheimer’s Disease. The Woodlands, TX – VGXI, Inc., an industry recognized… Read More »
VGXI New Manufacturing Facility Achieves Construction Milestones In Advance of 2022 Operational Date
Specialized GMP contract manufacturer VGXI, Inc. announced multiple construction milestones have been reached for its new headquarters and expanded manufacturing facility in Conroe, TX. The Woodlands, TX – VGXI, Inc., an industry leading contract developer and manufacturer (CDMO) for nucleic acid biopharmaceuticals including DNA vaccines and gene therapies, announced that its new… Read More »
Industry leading plasmid DNA Manufacturer VGXI, Inc. partners with Rare Trait Hope Fund in support of a gene therapy for the rare genetic disease, Aspartylglucosaminuria (AGU). The Woodlands, TX – Contract developer and manufacturer VGXI, Inc., which specializes in production of nucleic acid-based biopharmaceuticals for DNA vaccines and gene therapy applications, announced… Read More »
Texas-based plasmid DNA Manufacturer VGXI, Inc. Celebrates the Topping Out for its New Headquarters and Expanded Manufacturing Facility. The Woodlands, TX – VGXI, Inc., a highly specialized contract developer and manufacturer for DNA-based biopharmaceuticals, celebrated a significant milestone for its new headquarters and manufacturing facility with a topping out ceremony on Monday,… Read More »
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC). The Woodlands, TX – VGXI, Inc., an industry leading manufacturer for pre-clinical through cGMP clinical plasmid DNA, announced that its partner… Read More »
To our Valued Clients and Business Partners, Thank you for everyone’s concern regarding the severe winter storm conditions that swept through Texas during the week of 15Feb21. The VGXI offices remained closed for the week to ensure the safety of all our team members as they faced challenges from icy road conditions,… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Breaks Ground for New Conroe-based Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, held a groundbreaking ceremony on November 10, 2020 for its new greenfield manufacturing facility. The milestone event was hosted by VGXI in accordance… Read More »
Texas-based plasmid DNA CDMO VGXI, Inc. was recognized as the winner of the 2020 ViE Award for Best Contract Manufacturing Organization at the World Vaccine Congress Washington. The Woodlands, TX – VGXI, Inc., a contract development and manufacturing organization specialized in production of pre-clinical through cGMP grade DNA-based biopharmaceuticals, announced it has… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Completes Land Purchase and Proceeds with Design Development Phase for New Expanded Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has closed on the purchase of greenfield for a new, expanded manufacturing facility. The… Read More »
Update June 26, 2020: VGXI and GeneOne are pleased with the court’s decision in our favor protecting our company’s intellectual property rights. We have always been willing to manufacture any vaccine candidate for Covid-19, and want to help find a cure. Original Post on June 04, 2020: VGXI was surprised by Inovio’s… Read More »
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement. THE WOODLANDS,TX AND PLYMOUTH MEETING, PA – Leading plasmid DNA contract manufacturer VGXI, Inc. announced it has completed accelerated cGMP manufacturing of the first clinical batch of a personalized neoantigen vaccine for its client Geneos… Read More »